🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

📖 Top-read in TAM: The development of #PARPinhibitors in advanced #ProstateCancer. Check out the comprehensive review on therapeutic strategies and synergies: journals.sagepub.com/doi/10.1177/17… Authors: Maite Bourlon, Paola Valdez, Elena Castro

The ALEBRIJE study is out!! 🇲🇽 JCO Global Oncology ASCO #bladdercancer 🎉1st Mexican report: treatment trends mUC ⬆️ rates of progressive disease w platinum 🟢 Performace status, 1st line tx & visceral disease impact OS 🔴Unequal access to novel drugs Evelyn Beas INCMNSZ_Uronco

Inicia sesion de #GU25 #prostatecancer 🔴 PORTOS: Firma genética predictora respuesta a dosis RT 🟠 Comparación emulada aleatorizada PR vs RT en CaPr de alto riesgo 🔵 TALAPRO-2: SG final pobalción no seleccionada Neeraj Agarwal, MD, FASCO 🟢 STOPCAP matanálisis benevicio de ARSI en mCPHS

#ASCODailyNews @asco How to treat metastastic urothelial carcinoma after 1st line EV+Pembro? 🔴 Lack of evidence & need trials 🟠 Look @ proposed algorithm 🟢 Ongoing trials mUC after EV & ICIs 🔵 Table of efficacy outcomes of platinum, erdafitinib (FGFR3) & trastu deruxtecan

Take a time to read this #ASCODailyNews con how to select treatment after frontline Enfortumab Vedotin and Pembrolizumab! Maite Bourlon Paola Valdez Regina Barragan-Carrillo Thomas Flaig Tom Powles Andrea Apolo, M.D. Ray Manneh Kopp Fernando Sabino, MD, PhD INCMNSZ_Uronco

Maite Bourlon This is a question in clinic daily practice 🦀⁉️⚠️

What follows frontline EV+P in advanced urothelial cancer? Experts discuss potential solutions in the absence of definitive clinical trial data: brnw.ch/21wR6dO Maite Bourlon Paola Valdez Tom Powles Thomas Flaig #GUCSM #ASCODailyNews

INCMNSZ we were happy to receive Pedro C Barata, MD MSc FACP to discuss about #ProstateCancer 👨🏻‍⚕️👩🏻‍⚕️🌍🇲🇽 Multidisciplinary discussion w Urology, Genetics and pathology 📘🖇️🗂️💙 José Luis Rodríguez Sofía Elias

PEACE3: Early use of bone protecting agent (BPA) w Enza ± Radium 223 improved rPFS & OS. n=119 stratified according to use of BPA. 🟡 BPA improved rPFS by 14m (27m vs 13m, HR=0.60, 95%CI 0.39-0.93) ✅ 🟠 BPA improved OS by 17m (43m vs 26m, HR=0.56, 95%CI 0.37-0.86)✅

NIAGARA: Agregar durvalumab no impactó negativamente en los desenlaces quirúrgicos al comparar con quimioterapia 🔵Cistectomía: durva/qt 88% vs qt 83% 👍 🟣Cistectomía en los primeros 56 días post-tx : durva/qt 90% vs qt 90%☝️

Excelente plática con Pedro C Barata, MD MSc FACP Francisco Rodríguez-Covarrubias en INCMNSZ Instituto Nacional de Cancerología Oscar Arrieta Paula Cabrera Actualización TALAPRO-2: talazo+enza vs enza demostró… 🟨 Beneficio en SLPr y SG en pacientes no seleccionados (cohorte 1) 🟩 Beneficio en SLPr y SG en pacientes HRD (cohorte 2)

TALAPRO-2 (cohorte 1): Talazo + enza vs enza demostró beneficio en pacientes no seleccionados. 🟠SLPr: 33.1 vs 19.5 m (HR 0.66, 95%CI 0.55-0.80) ✅ 🔴SG: 45.8 vs 37.0 m (HR 0.79, 95%CI 0.66-0.95) ✅

TALAPRO-2 (cohorte 2): Talazo + enza vs enza demostró beneficio en población HRD. 🔵SLPr: 30.7 m vs 12.3 m (HR 0.47, 95%CI 0.35-0.61) ✅ 🟢SG: 45.1 m vs 31.1 m (HR 0.62, 95%CI 0.47-0.81) ✅ 🔶Análisis subgrupos: beneficio en BRCA1/2m y HRD no BRCA1/2m ✅

TALAPRO-2: Actualizaciòn de resultados cohorte 1 y 2

TALAPRO-2: Cohorte 1, beneficio en SLPr y SG en pacientes no seleccionados

TALAPRO 2: Beneficio en SLR y SG en HRD

🚨📢🚨Disitamab vedotina + toripalimab mejoró SG y SLP vs Gem+platino en pacientes con CUMI avanzado con sobreexpresión de HER2 (IHQ 1+, 2+, 3+) Grandes cambios el tratameinto de Cáncer Urotelial😍💪👩‍🔬🗣️ OncoAlert Uromigos Targeted Oncology

🎙️Radiografía actual (tabla) del uso de PD(L)1 en cáncer de vejiga: 👉🏻 14 ensayos fase 3 👉🏻> 8000 pacientes ¿Qué hemos aprendido? ✅Más eficacia en enfermedad temprana 🚫 Todavía sin biomarcador fiable 🧩 PD-1 ≈ PD-L1 en eficacia 🎯 Subgrupo que responde siempre (¿quiénes?)

Global Oncology voices #ASCO25 @asco 🟢GO is a nascent field & embraces inclusion 🟡 Networking w international colleagues is paramount 🟠 Mentoring w a GO perspective is key 🔴 Take advantage Conquer Cancer, the ASCO Foundation opportunities 🔵 Tailor, adapt & customize to the resource setting

Biggest RWD: Cabo/nivo 1st line #kidneycancer 🔴 N=333, 17 countries & 53 centers ARON project 🟠 mFU 15.9m, mOS not reached, mPFS 33.7m 🟢 ORR 58%, CR 6% 🟣 Poor prognosis: ECOG, sarcomatoid, brain & bone mets 🔵 ≥ G3 AE 37% (Hypertension & HFS) frontiersin.org/journals/oncol…